Precipio Diagnostics

69 articles about Precipio Diagnostics

• Precipio Announces Year end 2023 Shareholder Update Call

  3/25/2024

  Specialty cancer diagnostics company Precipio, Inc., will be hosting its year end 2023 corporate update call on April 1st, 2024 at 5:00 PM ET.

• Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY

  2/13/2024

  Specialty cancer diagnostics company Precipio, Inc., announces that for the full year of 2023, its unaudited revenues have grown from $9.4M in 2022 to $15.2M in 2023, an increase of 60% year over year.

• Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

  2/6/2024

  Specialty cancer diagnostics company Precipio, Inc. announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products.

• Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarterResults clearly demonstrate the business’s ability to reach breakeven in the near future

  1/23/2024

  Specialty cancer diagnostics company Precipio, Inc. announces that continued revenue growth generated cash levels that bring the company closer to breakeven.

• Precipio Announces Christina Valauri joins the Board of DirectorsDouglas Fisher, MD will step down as Director, and remain as a board observer

  1/2/2024

  Specialty cancer diagnostics company Precipio, Inc. is pleased to welcome Christina Valauri to its board of directors effective Jan 1st, 2024.

• Precipio Announces Q3-2023 Shareholder Update CallConference Call to be held on November 20th, 2023 at 5:00 PM EST

  11/16/2023

  Specialty cancer diagnostics company Precipio, Inc., will be hosting its Q3-2023 corporate update call on November 20th, 2023 at 5:00 PM ET.

• Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023

  10/3/2023

  Specialty cancer diagnostics company Precipio, Inc., announces that the combination of revenue growth and cost cutting initiatives has reduced Cash Burn From Operations by 59% compared to the same quarter last year, from approximately $2.5M/quarter to $1M/quarter.

• Precipio Continues to Sign New HemeScreen™ CustomersNew customer orders received in Q3 exceed $1M annualized revenue

  9/28/2023

  Specialty cancer diagnostics company Precipio, Inc. announced that new customer orders are expected to bring total Q4 HemeScreen revenues to an estimated $1.2M.

• Precipio Reduces Product Revenue Result Needed for Cash Flow BreakevenHigher pathology revenues and lower cost structure drive down product revenue breakeven point from $8M to $6M

  9/25/2023

  Specialty cancer diagnostics company Precipio, Inc. announced that due to the increased pathology revenue, and the recent operational efficiencies, the company has reduced the revenue required from the products division to reach breakeven from $8M to $6M annually, or $1.5M per quarter, 25% below previous estimates.

• Precipio Announces Q2-2023 Shareholder Update CallConference Call to be held on August 17, 2023 at 5:00 PM EST

  8/10/2023

  Specialty cancer diagnostics company Precipio, Inc., will be hosting its Q2-2023 corporate update call on August 17th at 5:00 PM ET.

• Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

  8/8/2023

  Specialty cancer diagnostics company Precipio, Inc., announces the launch of its new quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind on the market.

• Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023

  8/1/2023

  Specialty cancer diagnostics company Precipio, Inc., announces that Q2-2023 revenues have increased to $3.5M in Q2-2023 from $2.8M in Q1-2023, an increase of 25% QoQ.

• Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

  6/13/2023

  Specialty cancer diagnostics company Precipio, Inc., announces that it has entered into a collaboration agreement with a NY-based academic healthcare institution to jointly develop a panel for Glioblastoma, an aggressive brain cancer based on Precipio’s HemeScreen technology.

• Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

  6/8/2023

  Precipio, Inc. today announced it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 4,125,000 shares of the Company’s common stock and pre-funded warrants to purchase 319,445 shares of the Company’s common stock.

• Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects

  6/7/2023

  Specialty cancer diagnostics company Precipio, Inc., announces that several operational improvement initiatives which commenced at the start of the year have begun to impact the cash burn and bottom line profitability.

• Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® TechnologyPanel-Based Approach of Driver Mutation Detection Proves Crucial for Patient Care

  5/22/2023

  Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia and p210 isoform expression which allowed the lab to uncover an additional oncogene isoform expression.

• Precipio Shares Growth Catalysts For HemeScreenQ1 Results and catalysts show promising growth trajectory

  5/17/2023

  Specialty cancer diagnostics company Precipio, Inc., will be discussing on ’s shareholders call several growth catalysts that management has been tracking.

• Precipio Announces Q1-2023 Shareholder Update Call

  5/15/2023

  Specialty cancer diagnostics company Precipio, Inc., will be hosting its Q1-2023 corporate update call on May 17th at 5:00 PM ET.

• Precipio Signs Another HemeScreen™ Customer

  5/4/2023

  Specialty cancer diagnostics company Precipio, Inc. announces another agreement with a new customer to bring HemeScreen™ technology into their laboratory.

• Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

  5/4/2023

  Specialty cancer diagnostics company Precipio, Inc. announces another agreement with a new pathology services customer to utilize Precipio’s diagnostic services.